Artivion | CRY - Beneficio Bruto En Ventas

Precio De Mercado
35.42
Cambio Diario
0.69 1.99%
Mensual
-1.77%
Anual
24.15%
Q2 Expectativa
35.46




Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 5.86B 675M 2026-03
Accuray USD 41.89M 7.42M 2024-12
AngioDynamics USD 44.78M 2.93M 2025-09
Artivion USD 73.14M 1.25M 2025-12
AtriCure USD 109.31M 3.97M 2026-03
Baxter International USD 891M 314M 2026-03
Becton, Dickinson and Co. USD 2.41B 1.72B 2025-12
Boston Scientific USD 3.61B 64M 2026-03
Edwards Lifesciences USD 1.29B 59.4M 2026-03
Inogen USD 41.34M 1.39M 2024-09
Integra LifeSciences USD 213.21M 3.89M 2026-03
J&J USD 17.24B 642M 2026-03
Mesa Laboratories USD 39.75M 4.3M 2024-12
Orthofix International USD 153.28M 4.76M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
ResMed USD 890.98M 12.26M 2026-03
Stryker USD 3.81B 675M 2026-03
Surmodics USD 20.08M 31.62M 2025-06
Tandem Diabetes Care USD 167.46M 33.17M 2025-12
Teleflex USD 307.45M 144.2M 2025-12
Terumo JPY 153.19B 6.2B 2025-12
Trinity Biotech USD 6.47M 1.59M 2025-09